This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / MHRA Warns of Semaglutide Eye Risk
Regulatory drug side-effect warning

MHRA Warns of Semaglutide Eye Risk

Analysis based on 19 articles · First reported Feb 05, 2026 · Last updated Mar 11, 2026

Sentiment
-20
Attention
4
Articles
19
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market for Semaglutide-based drugs like Semaglutide and Semaglutide may experience negative sentiment and potential sales impact due to the new health warning. This could also lead to increased scrutiny on other GLP-1 receptor agonists.

Pharmaceuticals Healthcare
Event Summary

The United Kingdom===Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding a rare but serious eye condition, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), potentially linked to the use of Semaglutide, marketed as Semaglutide, Semaglutide, and Semaglutide. NAION causes sudden vision loss due to reduced blood flow to the optic nerve. While the risk is considered extremely small, the MHRA advises patients and healthcare professionals to be vigilant for symptoms and seek urgent medical attention if they occur. This warning follows a previous alert about acute pancreatitis linked to these medications. Research by Joseph Rizzo indicated a higher risk of NAION in Semaglutide users, though he cautioned against stopping medication. The International===European Medicines Agency also concluded NAION is a very rare side effect. The increasing use of these drugs for type 2 diabetes and weight management highlights the importance of ongoing safety monitoring.

Key Actions
95 Novo Nordisk===Semaglutide linked to increased risk of non-arteritic anterior ischemic optic neuropathy
80 Novo Nordisk manufactures semaglutide drugs
70 United Kingdom===Medicines and Healthcare products Regulatory Agency issued drug safety update warning about NAION risk
60 United States===Food and Drug Administration maintains adverse event reporting system used for study
60 European Union===European Medicines Agency issued similar warnings about NAION risk
50 Novo Nordisk updated EU patient leaflets to include NAION
Entities Involved
stock
Novo Nordisk
Novo Nordisk manufactures Novo Nordisk===Semaglutide, Novo Nordisk===Semaglutide, and Novo Nordisk===Semaglutide. The study's findings, particularly the increased risk associated with Novo Nordisk===Semaglutide, could lead to scrutiny of Novo Nordisk's products and potentially affect its stock price and reputation, despite the company's stance that the benefit-risk profile remains favorable.
Importance 100 Sentiment -25
govactor
United Kingdom===Medicines and Healthcare products Regulatory Agency
The United Kingdom===Medicines and Healthcare products Regulatory Agency issued a warning regarding the potential link between semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), and also previously warned about acute pancreatitis. This demonstrates their role in ensuring drug safety.
Importance 90 Sentiment 0
per
Alison Cave
Alison Cave, the Chief Safety Officer of the United Kingdom===Medicines and Healthcare products Regulatory Agency, emphasized the importance of patient safety and awareness regarding the potential side effects of Semaglutide.
Importance 60 Sentiment 0
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration (FDA) is the US medicines regulator whose adverse event reporting system was used for the study. The FDA's role in monitoring drug safety and potential future actions based on these findings are important.
Importance 60 Sentiment 0
per
Joseph Rizzo
Joseph Rizzo, a Mass General Brigham ophthalmologist, conducted a study indicating a possible link between Semaglutide and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), but cautioned against stopping medication based solely on these findings.
Importance 50 Sentiment 0
subs
Novo Nordisk===Semaglutide
Novo Nordisk===Semaglutide, an oral semaglutide tablet, showed no increased risk of NAION in the study. Its limited absorption and slower uptake are suggested as reasons for this, potentially positioning it as a safer alternative within the semaglutide family for this specific side effect.
Importance 50 Sentiment 0
govactor
International===European Medicines Agency
The International===European Medicines Agency concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a very rare side effect of Semaglutide medicines, corroborating the United Kingdom===Medicines and Healthcare products Regulatory Agency's findings.
Importance 40 Sentiment 0
+ 4 more entities View on Dashboard
Relationships
Alison Cave related ↔ United Kingdom===Medicines and Healthcare products Regulatory Agency
Joseph Rizzo related ↔ Mass General Brigham
Novo Nordisk related ↔ Novo Nordisk===Semaglutide
Novo Nordisk related ↔ Novo Nordisk===Semaglutide
Novo Nordisk related ↔ Novo Nordisk===Semaglutide
United States===Food and Drug Administration related ↔ Novo Nordisk
United Kingdom===Medicines and Healthcare products Regulatory Agency related ↔ Novo Nordisk
European Union===European Medicines Agency related ↔ Novo Nordisk
Novo Nordisk===Semaglutide related ↔ Novo Nordisk===Semaglutide
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.